Hadasit Bio
HBL - Hadasit Bio-Holdings Ltd operates in the biotechnology industry in Israel. It operates in the fields of oncology, regenerative medicine, and inflammatory disease. The company develops biological drugs; and plasma RNA biomarkers for colorectal cancer. It offers ProtAb, an immunotherapeutic monoclonal antibody for the treatment of autoimmune inflammatory diseases. HBL - Hadasit Bio-Holdings L… Read more
Hadasit Bio (HDST) - Net Assets
Latest net assets as of June 2023: ILA10.94 Million ILA
Based on the latest financial reports, Hadasit Bio (HDST) has net assets worth ILA10.94 Million ILA as of June 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA14.67 Million) and total liabilities (ILA3.73 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ILA10.94 Million |
| % of Total Assets | 74.61% |
| Annual Growth Rate | 5.03% |
| 5-Year Change | 2.26% |
| 10-Year Change | 40.95% |
| Growth Volatility | 162.41 |
Hadasit Bio - Net Assets Trend (2008–2022)
This chart illustrates how Hadasit Bio's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Hadasit Bio (2008–2022)
The table below shows the annual net assets of Hadasit Bio from 2008 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | ILA35.08 Million | -46.60% |
| 2021-12-31 | ILA65.69 Million | +77.03% |
| 2020-12-31 | ILA37.11 Million | +574.57% |
| 2019-12-31 | ILA5.50 Million | -83.96% |
| 2018-12-31 | ILA34.30 Million | -43.57% |
| 2017-12-31 | ILA60.79 Million | -1.35% |
| 2016-12-31 | ILA61.62 Million | +2.19% |
| 2015-12-31 | ILA60.30 Million | +172.71% |
| 2014-12-31 | ILA22.11 Million | -11.15% |
| 2013-12-31 | ILA24.89 Million | -30.60% |
| 2012-12-31 | ILA35.86 Million | +0.70% |
| 2011-12-31 | ILA35.61 Million | -32.88% |
| 2010-12-31 | ILA53.06 Million | +8.21% |
| 2009-12-31 | ILA49.03 Million | +178.01% |
| 2008-12-31 | ILA17.64 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Hadasit Bio's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10570300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ILA140.78 Million | 401.34% |
| Total Equity | ILA35.08 Million | 100.00% |
Hadasit Bio Competitors by Market Cap
The table below lists competitors of Hadasit Bio ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
LHC
VN:LHC
|
$37.30K |
|
COMPUTER MODELLING
BE:5TJ
|
$37.31K |
|
Biome Grow Inc
PINK:BIOIF
|
$37.31K |
|
Sonovia Ltd
TA:SONO
|
$37.36K |
|
C3is Inc.
NASDAQ:CISS
|
$37.22K |
|
KORIAN (KO2.SG)
STU:KO2
|
$37.16K |
|
TAMINCO
F:T4M
|
$37.13K |
|
ViroMed Co Ltd
KO:084990
|
$37.10K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hadasit Bio's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from 65,692,000 to 35,078,000, a change of -30,614,000 (-46.6%).
- Net loss of 31,211,000 reduced equity.
- Other factors increased equity by 597,000.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ILA-31.21 Million | -88.98% |
| Other Changes | ILA597.00K | +1.7% |
| Total Change | ILA- | -46.60% |
Book Value vs Market Value Analysis
This analysis compares Hadasit Bio's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 17.10x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 17.33x to 17.10x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ILA3.12 | ILA54.10 | x |
| 2018-12-31 | ILA3.10 | ILA54.10 | x |
| 2019-12-31 | ILA0.49 | ILA54.10 | x |
| 2020-12-31 | ILA3.34 | ILA54.10 | x |
| 2021-12-31 | ILA5.92 | ILA54.10 | x |
| 2022-12-31 | ILA3.16 | ILA54.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hadasit Bio utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -88.98%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.11x
- Recent ROE (-88.98%) is below the historical average (-59.91%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -84.74% | 0.00% | 0.00x | 1.94x | ILA-16.98 Million |
| 2014 | -42.34% | 0.00% | 0.00x | 2.16x | ILA-7.86 Million |
| 2015 | -128.11% | 0.00% | 0.00x | 5.28x | ILA-17.94 Million |
| 2016 | -9.92% | 0.00% | 0.00x | 4.22x | ILA-3.28 Million |
| 2017 | 38.25% | 3659.44% | 0.01x | 1.99x | ILA9.73 Million |
| 2018 | -0.92% | -126.40% | 0.01x | 1.03x | ILA-3.74 Million |
| 2019 | -409.76% | -96934.78% | 0.00x | 1.73x | ILA-22.84 Million |
| 2020 | 84.26% | 0.00% | 0.00x | 1.12x | ILA27.50 Million |
| 2021 | 43.18% | 0.00% | 0.00x | 1.01x | ILA21.79 Million |
| 2022 | -88.98% | 0.00% | 0.00x | 1.11x | ILA-34.72 Million |
Industry Comparison
This section compares Hadasit Bio's net assets metrics with peer companies in the Biotechnology & Medical Research industry.
Industry Context
- Industry: Biotechnology & Medical Research
- Average net assets among peers: $57,151,000
- Average return on equity (ROE) among peers: -87.25%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hadasit Bio (HDST) | ILA10.94 Million | -84.74% | 0.34x | $37.28K |
| Pluristem (PSTI) | $57.15 Million | -87.25% | 0.64x | $313.59K |